

CellDetect® Staining Kit

Innovative cytopathology stain
highlighting malignant cells
in urine specimens

- Non-invasive
- Standard workflow
- Cost-effective






An innovative staining technology combining color and morphology to distinguish between normal and neoplastic cells

Urothelial Cell Carcinoma

Urothelial cell carcinoma is the most common malignancy of the urinary system. While only relying on cytomorphological features, the standard staining method does not always provide optimal results for the detection of low-grade, early stage cancer cells in urine smears.

CellDetect® Staining Kit

The CellDetect® Staining Kit is designed as a time-efficient method for differential staining of malignant cells in urine specimens.



Standard Stain	CellDetect® Stain
<p>Neoplastic Cells</p> <p>Normal Cells</p>	<p>Neoplastic Cells</p> <p>Normal Cells</p>
<p>Interpretation based on morphology only</p>	<p>Interpretation based on color and morphology</p>

With CellDetect®, the nucleus of suspicious cells is highlighted in reddish-purple, complementing the morphological analysis.

CellDetect® Procedure

Using standard cytology lab equipment, the CellDetect® staining process takes around 20 minutes and can be performed manually or in automated slide staining systems.

Micromedic Technologies (TASE: MCTC) is engaged in the development and commercialization of unique solutions addressing real needs prevailing in the field of cancer diagnostics and early cancer detection. CellDetect® is a Trademark of ZetiQ, a fully-owned subsidiary of Micromedic.

Bladder Cancer Facts

- 4th most common cancer among men in the United States
- 2.7 million people with history of bladder cancer worldwide
- 430,000 new bladder cancers diagnosed annually


Source: *Globocan 2012*



Special staining kit featuring unique plant extract



Utilizes standard lab processes and equipment



Compatible with majority of urine specimens

Importance of early detection

5-year survival rate decreases from 96% for patients with flat bladder cancer tumors to 5.5% for patients with distant lesions.

Source: *SEER Cancer Stat. 2014*



References

- Davis et al. *European Urology Focus* 2016
 Davis et al. *Journal of Urology* 2014; 192:1628-1632
 Idelevich et al. *Diagnostic Cytopathology* 2012; 40:1054-1061
 Sagiv et al. *Journal of Carcinogenesis* 2009; 8:16-23



US Agent
 Qsite US
 77 Dorcar Rd.
 Newton, MA 02459
 Tel (512) 5354930
 Fax (512) 5356103